CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical and radiation oncologists, nurses, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of higher-risk myelodysplastic syndromes.
  
  LEARNING OBJECTIVES

  • Appreciate the value of molecular testing for patients with myelodysplastic syndromes (MDS), and determine how various genetic alterations may affect MDS classification and risk assessment.
  • Evaluate the importance of age, performance status, cytogenetic profile and other patient- and disease-related factors in the selection and sequencing of therapy for higher-risk MDS.
  • Recognize the FDA approval of oral hypomethylating agent therapy for intermediate- and high-risk MDS, and identify patients for whom treatment with this novel approach may be appropriate.
  • Describe the biological rationale for and available research findings with Bcl-2-targeted therapy for high-risk MDS, and appraise the role of this strategy in current and future clinical care.
  • Assess the scientific justification for and published research findings with novel agents targeting CD47 in MDS to determine the potential clinical applicability of these approaches.
  • Develop an understanding of the mechanisms of action of and available data with other investigational approaches for higher-risk MDS in order to prepare for their potential availability in routine practice.
  • Implement a plan to manage the side effects associated with approved and investigational therapies for MDS to support quality of life and continuation of treatment.
  • Recollect the designs of ongoing clinical trials for high-risk MDS, and counsel appropriate patients about the potential benefits of participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% and fill out the Educational Assessment and Credit Form. Program location URLs are noted below:
  
  Audio Interview: Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  Presentations Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Guillermo Garcia-Manero, MD
  McCredie Professor of Medicine
  Chief, Section of MDS
  Vice Chair, Department of Leukemia
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  No relevant conflicts of interest to disclose.
  
  David Sallman, MD
  Associate Member
  Malignant Hematology
  Moffitt Cancer Center
  Tampa, Florida
  
  Advisory Committee: AvenCell, bluebird bio, Bristol Myers Squibb, Intellia Therapeutics, Jasper Therapeutics Inc, Kite, A Gilead Company, Magenta Therapeutics, Nkarta Inc, Novartis, Servier Pharmaceuticals LLC, Shattuck Labs, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Affimed GmbH, Gilead Sciences Inc, Incyte Corporation, Molecular Partners, Precigen Inc, Takeda Pharmaceuticals USA Inc, Zentalis Pharmaceuticals; Contracted Research: Aprea Therapeutics, Jazz Pharmaceuticals Inc; Nonrelevant Financial Relationship: Intellisphere Oncology Specialty Group.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by an educational grant from Gilead Sciences Inc.
  
  Release date: August 2023
  Expiration date: August 2024